Metformin Versus Orlistat in Obese Polycystic Ovary Syndrome (PCOS) Patients

Yazd Research & Clinical Center for Infertility80 enrolled

Overview

The purpose of this study is to compare the influence of Orlistat and Metformin on obesity treatment in obese PCOS women.

In a randomized clinical trial study, 80 obese women with BMI≥30, oligomenorrhae, hirsutism and presence of \> 12 ovarian follicles (2-10mm diameter), were evaluated. In metformin group , metformin was administered for patients 1500 mg daily for three months. In orlistate group, patients used orlistat tablets (120 mg, 3 times a day) for three months. BMI, serum LH and FSH levels, serum triglyceride and cholesterol levels and also patients' ovulation was compared before and after treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Obesity

Interventions

orlistatDRUG

Tablet,120mg,three times a day,three months

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * BMI\>= 30 * PCOS Exclusion Criteria: * Drug use during last three months

Locations (1)

Research and Clinical Center for Infertility

Yazd, Iran

Outcomes

Primary Outcomes

Body Mass Index (BMI)

Time frame: 3 months

Secondary Outcomes

Ovulatory

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.